These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33604571)

  • 1. Development of novel bioassays to detect soluble and aggregated Huntingtin proteins on three technology platforms.
    Landles C; Milton RE; Jean A; McLarnon S; McAteer SJ; Taxy BA; Osborne GF; Zhang C; Duan W; Howland D; Bates GP
    Brain Commun; 2021; 3(1):fcaa231. PubMed ID: 33604571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early detection of exon 1 huntingtin aggregation in zQ175 brains by molecular and histological approaches.
    Smith EJ; Sathasivam K; Landles C; Osborne GF; Mason MA; Gomez-Paredes C; Taxy BA; Milton RE; Ast A; Schindler F; Zhang C; Duan W; Wanker EE; Bates GP
    Brain Commun; 2023; 5(1):fcad010. PubMed ID: 36756307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.
    Aldous SG; Smith EJ; Landles C; Osborne GF; Cañibano-Pico M; Nita IM; Phillips J; Zhang Y; Jin B; Hirst MB; Benn CL; Bond BC; Edelmann W; Greene JR; Bates GP
    Brain; 2024 May; 147(5):1784-1798. PubMed ID: 38387080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative processing of human HTT mRNA with implications for Huntington's disease therapeutics.
    Fienko S; Landles C; Sathasivam K; McAteer SJ; Milton RE; Osborne GF; Smith EJ; Jones ST; Bondulich MK; Danby ECE; Phillips J; Taxy BA; Kordasiewicz HB; Bates GP
    Brain; 2022 Dec; 145(12):4409-4424. PubMed ID: 35793238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcellular Localization And Formation Of Huntingtin Aggregates Correlates With Symptom Onset And Progression In A Huntington'S Disease Model.
    Landles C; Milton RE; Ali N; Flomen R; Flower M; Schindler F; Gomez-Paredes C; Bondulich MK; Osborne GF; Goodwin D; Salsbury G; Benn CL; Sathasivam K; Smith EJ; Tabrizi SJ; Wanker EE; Bates GP
    Brain Commun; 2020; 2(2):fcaa066. PubMed ID: 32954323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meso scale discovery-based assays for the detection of aggregated huntingtin.
    Reindl W; Baldo B; Schulz J; Janack I; Lindner I; Kleinschmidt M; Sedaghat Y; Thiede C; Tillack K; Schmidt C; Cardaun I; Schwagarus T; Herrmann F; Hotze M; Osborne GF; Herrmann S; Weiss A; Zerbinatti C; Bates GP; Bard J; Munoz-Sanjuan I; Macdonald D
    PLoS One; 2019; 14(3):e0213521. PubMed ID: 30913220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyglutamine- and temperature-dependent conformational rigidity in mutant huntingtin revealed by immunoassays and circular dichroism spectroscopy.
    Fodale V; Kegulian NC; Verani M; Cariulo C; Azzollini L; Petricca L; Daldin M; Boggio R; Padova A; Kuhn R; Pacifici R; Macdonald D; Schoenfeld RC; Park H; Isas JM; Langen R; Weiss A; Caricasole A
    PLoS One; 2014; 9(12):e112262. PubMed ID: 25464275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.
    Franich NR; Hickey MA; Zhu C; Osborne GF; Ali N; Chu T; Bove NH; Lemesre V; Lerner RP; Zeitlin SO; Howland D; Neueder A; Landles C; Bates GP; Chesselet MF
    J Neurosci Res; 2019 Dec; 97(12):1590-1605. PubMed ID: 31282030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Splice modulators target PMS1 to reduce somatic expansion of the Huntington's disease-associated CAG repeat.
    McLean ZL; Gao D; Correia K; Roy JCL; Shibata S; Farnum IN; Valdepenas-Mellor Z; Kovalenko M; Rapuru M; Morini E; Ruliera J; Gillis T; Lucente D; Kleinstiver BP; Lee JM; MacDonald ME; Wheeler VC; Mouro Pinto R; Gusella JF
    Nat Commun; 2024 Apr; 15(1):3182. PubMed ID: 38609352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice.
    Gu X; Richman J; Langfelder P; Wang N; Zhang S; Bañez-Coronel M; Wang HB; Yang L; Ramanathan L; Deng L; Park CS; Choi CR; Cantle JP; Gao F; Gray M; Coppola G; Bates GP; Ranum LPW; Horvath S; Colwell CS; Yang XW
    Neuron; 2022 Apr; 110(7):1173-1192.e7. PubMed ID: 35114102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of mAb-based polyglutamine-dependent and polyglutamine length-independent huntingtin quantification assays with cross-site validation.
    Fischer DF; Dijkstra S; Lo K; Suijker J; Correia ACP; Naud P; Poirier M; Tessari MA; Boogaard I; Flynn G; Visser M; Lamers MBAC; McAllister G; Munoz-Sanjuan I; Macdonald D
    PLoS One; 2022; 17(4):e0266812. PubMed ID: 35395060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis.
    Gipson TA; Neueder A; Wexler NS; Bates GP; Housman D
    RNA Biol; 2013 Nov; 10(11):1647-52. PubMed ID: 24256709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification assays for total and polyglutamine-expanded huntingtin proteins.
    Macdonald D; Tessari MA; Boogaard I; Smith M; Pulli K; Szynol A; Albertus F; Lamers MB; Dijkstra S; Kordt D; Reindl W; Herrmann F; McAllister G; Fischer DF; Munoz-Sanjuan I
    PLoS One; 2014; 9(5):e96854. PubMed ID: 24816435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation.
    Wang J; Gines S; MacDonald ME; Gusella JF
    BMC Neurosci; 2005 Jan; 6():1. PubMed ID: 15649316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse.
    Cowin RM; Roscic A; Bui N; Graham D; Paganetti P; Jankowsky JL; Weiss A; Paylor R
    Behav Brain Res; 2012 Apr; 229(2):308-19. PubMed ID: 22306231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.
    Lloret A; Dragileva E; Teed A; Espinola J; Fossale E; Gillis T; Lopez E; Myers RH; MacDonald ME; Wheeler VC
    Hum Mol Genet; 2006 Jun; 15(12):2015-24. PubMed ID: 16687439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Therapies for Huntington's Disease - Focus on N-Terminal Huntingtin and Huntingtin Exon 1.
    van der Bent ML; Evers MM; Vallès A
    Biologics; 2022; 16():141-160. PubMed ID: 36213816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of Huntington's disease by short tandem repeats.
    Hong EP; Ramos EM; Aziz NA; Massey TH; McAllister B; Lobanov S; Jones L; Holmans P; Kwak S; Orth M; Ciosi M; Lomeikaite V; Monckton DG; Long JD; Lucente D; Wheeler VC; Gillis T; MacDonald ME; Sequeiros J; Gusella JF; Lee JM
    Brain Commun; 2024; 6(2):fcae016. PubMed ID: 38449714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modifiers of Somatic Repeat Instability in Mouse Models of Friedreich Ataxia and the Fragile X-Related Disorders: Implications for the Mechanism of Somatic Expansion in Huntington's Disease.
    Zhao X; Kumari D; Miller CJ; Kim GY; Hayward B; Vitalo AG; Pinto RM; Usdin K
    J Huntingtons Dis; 2021; 10(1):149-163. PubMed ID: 33579860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.